A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry

L. M. Knapen, S. M. E. Geurts, K. I. E. Ibragimova, S. Croes, B. E. P. J. Vriens, F. W. P. J. van den Berkmortel, M. W. Dercksen, A. J. van de Wouw, M. J. A. E. Pepels, A. O. J. de Fallois, D. J. A. Lobbezoo, M. de Boer, V. C. G. Tjan-Heijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalBreast
Volume44
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Advanced breast cancer
  • Metastatic breast cancer
  • Everolimus
  • Hormone-receptor-positive
  • Real life
  • Progression-free survival
  • AROMATASE INHIBITORS
  • TRIAL
  • CHEMOTHERAPY
  • MULTICENTER
  • EFFICACY
  • THERAPY
  • SAFETY

Cite this